Vitreous substitution therapy after pediatric vitrectomy is a key challenge urgently needing to be addressed in the global ophthalmology field. In cases of retinal/choroidal detachment caused by severe ocular trauma or complex retinal detachment, the clinical application of traditional tamponades such as silicone oil is prone to inducing life-threatening complications like silicone oil-dependent eye and eyeball atrophy. Currently, there is no ideal solution to this therapeutic dilemma worldwide; especially for pediatric patients with immature eyeball development, the difficulty of eye preservation is further heightened, resulting in a persistently high enucleation rate in this group.
In 2025, China's independently developed Foldable Capsular Vitreous Body (FCVB) emerged, completely breaking the therapeutic bottleneck and becoming the global benchmark for eye-preserving treatment of severe ocular trauma. As a leader in the clinical application of this technology, Professor Liang Tianwei from the Department of Ophthalmology at Beijing Kingmed Children's Hospital has dedicated years to the field of pediatric ocular trauma. With exquisite medical skills and rich clinical experience, he has demonstrated the remarkable efficacy of FCVB technology in pediatric patients. Not only has it brought hope for eye preservation to domestic children, but it has also attracted global attention with the strength of Chinese original technology, becoming the core driving force for overseas patients to travel to Beijing for high-end ophthalmic treatment.
• Chief Physician, Distinguished Expert, Doctor of Ophthalmology, Department of Ophthalmology, Beijing Kingmed Children's Hospital
• Member, Pediatric Retina Group, Ophthalmology Committee of Cross-Strait Medicine Exchange Association
• Member, Retinal Disease and Infectious Ophthalmopathy Branch, Beijing Medical Doctor Association
• Member, Ophthalmic Inspection and Testing Group, Ophthalmology Professional Committee of China Medical Equipment Association
• Member, Glaucoma Group, Ophthalmology Committee of Beijing Perioperative Medicine Research Association
• Core Member, Beijing Integrated Traditional Chinese and Western Medicine Expert Consultation Center for Refractory Ophthalmic Diseases
https://jdetyy.com/dr.-liang-tianwei/
As one of the earliest experts in China to carry out the clinical application of FCVB technology, Professor Liang Tianwei has focused on the diagnosis and treatment of pediatric ocular trauma and fundus diseases for decades, devoting himself to the clinical transformation and optimization of Chinese original technology. He has led and participated in multiple FCVB-related clinical studies, completing hundreds of complex eye-preserving surgeries for pediatric ocular trauma, including a large number of difficult cases referred from overseas. With precise grasp of surgical indications, pursuit of ultimate precision in intraoperative operations, and effective prevention and control of postoperative complications, Professor Liang Tianwei's surgical success rate and patient satisfaction have always been at the leading level in the industry. He has become a recognized authoritative expert in pediatric FCVB treatment at home and abroad, and his clinical experience has been incorporated into multiple industry standards, leading the development direction of this field in China.
FCVB is an innovative ophthalmic technology independently developed by China with complete independent intellectual property rights. It fills the gap in vitreous substitution therapy after severe ocular trauma worldwide and breaks the long-term monopoly of overseas countries in the field of high-end ophthalmic medical devices. Compared with traditional silicone oil tamponade, this Chinese original technology demonstrates three core revolutionary advantages:
1. Maximized Eye-Preserving Effect: By simulating the spherical structure of the human natural vitreous body, it accurately fills the vitreous cavity, fundamentally preventing eyeball atrophy and retaining the normal appearance of the eye. For pediatric patients, it further ensures the spatial stability of eyeball development, avoiding subsequent problems such as facial developmental asymmetry caused by eyeball atrophy.
2. Pediatric-Specific Design: There is no need for patients to maintain a prone position for a long time after surgery, completely solving the clinical pain point of low cooperation among pediatric patients. At the same time, it significantly reduces the risk of complications such as glaucoma and corneal opacity caused by silicone oil dependence and emulsification, with a shorter treatment cycle and less trauma.
3. Comprehensive Coverage of Complex Cases: FCVB can provide effective solutions for difficult cases that are difficult to treat with traditional therapies, such as silicone oil-dependent eyes, the risk of atrophy after eyeball rupture surgery, and sequelae of endophthalmitis. Its scope of application is far beyond that of traditional substitutes.
This Chinese original technology has passed multiple clinical verifications, and relevant research results have been published in top international ophthalmic journals, gaining high recognition from the global ophthalmic community and becoming a core calling card for Chinese ophthalmic technology to go global.
Classic Cases Verify: Global Diagnostic and Therapeutic Strength of Chinese Technology and Experts
Case 1: 5-Year Silicone Oil-Dependent Eye - FCVB Ends the Dilemma of Repeated Surgeries
A 10-year-old girl suffered severe ocular trauma to her left eye after being stabbed by a pencil. Over 5 years, she successively underwent intraocular foreign body removal, cataract extraction, and 2 silicone oil tamponade and replacement surgeries, eventually developing a silicone oil-dependent eye with symptoms such as photophobia, corneal epithelial degeneration, and abnormal intraocular pressure. Multiple overseas hospitals recommended enucleation.
Examination Findings: No light perception in the left eye, severe ocular irritation (+ +), corneal epithelial degeneration, residual silicone oil in the anterior chamber, grayish-white retinal organization, intraocular pressure T-2, axial length (right eye/left eye) 22.9/20.7mm (the left eye showed signs of atrophy).
Professor Liang Tianwei's Treatment Plan: After accurately evaluating the axial length and eyeball structure, he performed left eye silicone oil removal + FCVB implantation combined with silicone oil injection. Postoperatively, personalized interventions were adopted for complications such as shallow anterior chamber and intraocular hemorrhage.
Prognosis: One year after surgery, the child's eyeball appearance was completely normal without irritation, and the intraocular pressure was stably maintained at around 5mmHg with an accurately positioned balloon. She was completely freed from the pain of repeated surgeries. The family specially expressed their gratitude: "It is Chinese technology and Professor Liang's medical skills that saved the child's eye!"
Case 2: Early Eyeball Atrophy After Traffic Accident - FCVB Reverses the Condition
A 9-year-old boy suffered a ruptured left eye in a traffic accident 2 years ago. After primary suture, secondary vitrectomy + retinal reattachment + silicone oil injection, he developed a silicone oil-dependent eye. His cornea gradually turned white, and the eyeball showed signs of early atrophy. Overseas experts evaluated the eye-preserving success rate as less than 10%. The parents traveled to multiple countries before seeking medical treatment in Beijing.
Examination Findings: Only light perception in the left eye, band keratopathy, emulsified silicone oil droplets in the anterior chamber, uneven retinal organization, axial length (right eye/left eye) 23.54/20.67mm (the left eye was significantly shorter than the right eye).
Diagnosis: Left eye silicone oil-dependent eye, silicone oil emulsification, early eyeball atrophy, corneal degeneration.
Professor Liang Tianwei's Treatment Plan: He performed left eye silicone oil removal + FCVB implantation combined with silicone oil injection. During the operation, the ciliary body was accurately exposed to avoid damage to normal ocular tissues.
Prognosis: Seven months after surgery, the cornea of the left eye was significantly clearer than before, the intraocular pressure was stably maintained at 3.8mmHg, the anterior chamber was moderately deep, and the balloon was well-positioned. The appearance of the left eye was symmetrical to that of the right eye. The parents sighed: "The technology of Chinese experts is more exquisite than that of the top overseas hospitals we consulted. FCVB technology has truly worked a miracle!"
Case 3: Risk of Eyeball Atrophy After Iron Wire Puncture - FCVB Guards the Hope of Eye Preservation
An 8-year-old girl developed endophthalmitis after her left eye was punctured by an iron wire. After treatment such as eyeball rupture repair and vitrectomy, signs of eyeball atrophy appeared. The parents strongly hoped to retain the eyeball and contacted Professor Liang Tianwei through an international medical referral channel.
Examination Findings: No light perception in the left eye, intraocular pressure 3mmHg, central corneal depression with visible rust deposition, mydriasis to 9mm, vitreous hemorrhage, axial length (right eye/left eye) 23.29/19mm (significant atrophy of the left eye).
Professor Liang Tianwei's Treatment Plan: One week before surgery, intravitreal injection of anti-VEGF drugs was accurately administered, followed by FCVB implantation combined with silicone oil injection. The entire process was minimally invasive to maximize the protection of ocular tissues.
Prognosis: Five months after surgery, the child's eyeball appearance was normal without discomfort. A local re-examination showed an intraocular pressure of 6mmHg and a stably positioned balloon, successfully avoiding enucleation. This has become a classic case of overseas referral for Chinese medical services.
Professor Liang Tianwei pointed out that the originality and clinical advantages of FCVB technology, as well as the in-depth efforts of Chinese ophthalmologists in this field, have made Beijing a "destination city" for global eye-preserving treatment of severe pediatric ocular trauma. For overseas patients, the core reasons for choosing treatment in Beijing lie in two irreplaceable advantages:
1. Technological Exclusivity: As a Chinese original technology, FCVB has the most mature clinical application system in China. Patients can directly access the world's leading treatment plans without waiting for overseas technology introduction or clinical trials.
2. Expert Authority: Chinese experts represented by Professor Liang Tianwei have accumulated the world's largest number of case experiences in the clinical application of FCVB. They can formulate personalized diagnosis and treatment plans for complex cases referred from overseas, ensuring higher surgical precision and better prognostic effects.
3. Cost-Effectiveness Advantage in Diagnosis and Treatment: Compared with similar high-end ophthalmic treatments overseas, China offers more reasonable medical expenses and more efficient diagnosis and treatment processes. Meanwhile, Beijing Kingmed Children's Hospital provides exclusive green channels for overseas patients, covering one-stop services such as translation, accommodation coordination, and postoperative follow-up, making medical treatment more convenient and reassuring for global patients.
EN
CN